VIJAY NAMBI to Clinical Trials as Topic
This is a "connection" page, showing publications VIJAY NAMBI has written about Clinical Trials as Topic.
Connection Strength
0.686
-
The future of hypertension pharmacotherapy: Ongoing and future clinical trials for hypertension. Curr Probl Cardiol. 2025 Jan; 50(1):102922.
Score: 0.154
-
Ongoing and future clinical trials of device therapies for patients with heart failure. Curr Probl Cardiol. 2024 Nov; 49(11):102805.
Score: 0.151
-
Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure. Am J Cardiovasc Drugs. 2024 Jul; 24(4):481-504.
Score: 0.150
-
The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis. Curr Atheroscler Rep. 2007 Aug; 9(2):97-103.
Score: 0.046
-
Role of biomarkers in developing new therapies for vascular disease. World J Surg. 2007 Apr; 31(4):676-81.
Score: 0.045
-
Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk. Curr Atheroscler Rep. 2005 Feb; 7(1):22-8.
Score: 0.039
-
ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients. Curr Atheroscler Rep. 2004 Sep; 6(5):353-8.
Score: 0.038
-
Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Circulation. 2019 03 05; 139(10):1341-1343.
Score: 0.026
-
Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
Score: 0.026
-
Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical management. World J Surg. 2007 Apr; 31(4):695-704.
Score: 0.011